Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 38

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 38
---
     | You should read the “Risk                                                                                                              
 Factors” section starting on page 25 of this prospectus for a discussion of factors to consider carefully before deciding              
 to invest in our securities.                                                                                                           |
| Nasdaq                                        
 symbol                                        |     | “NIVF” (Class                                                                                                                          
 A Ordinary Shares); “NIVFW” (Warrants to purchase Class A Ordinary Shares).                                                            |

The number of Ordinary Shares issued and outstanding is 2,952,702 as of October 31, 2025. No new Class A Ordinary Shares will be issued by us under this offering.

<div align='center'>24

RISK FACTORS</div>

Investing in our Class A
Ordinary Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors described
under the caption “Risk Factors” in any applicable prospectus supplement and any risk factors set forth in our other
filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, before making a decision about investing in our Class A Ordinary Shares. The risks and uncertainties we have described are not the
only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect
our operations. If any risks actually occur, our business, financial condition and results of operations may be materially and adversely
affected. In such an event, the trading price of our Class A Ordinary Shares could decline and you could lose part or all of your investment.

Additionally, we are also
subject to the following risk factors.

Risks Related to NewGenIvf’s Business and Industry

We may not be able to continue operating as a going concern.

As of June 30, 2025, the
Company’s cash and cash equivalents stood at approximately US$1,608,475. While the Company does not have immediate challenges to
settle its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge potential
financial and liquidity shortfalls.

The Company is always closely monitoring the market for opportunities and has also been carrying out various fundraising projects to improve the Company’s cash flow position. As of April 10, 2025, all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note, the First